Odonate (ODTC) Stock Overview
A pharmaceutical company, develops therapeutics for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ODTC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Odonate, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$150,000.00 |
| 52 Week High | US$176,040.00 |
| 52 Week Low | US$22,796.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 9.65% |
| 3 Year Change | 29.31% |
| 5 Year Change | -93.22% |
| Change since IPO | -91.85% |
Recent News & Updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Recent updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares
Jan 07Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
Dec 09
Shareholder Returns
| ODTC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.3% |
| 1Y | 9.6% | 28.0% | 16.2% |
Return vs Industry: ODTC exceeded the US Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: ODTC matched the US Market which returned 10.1% over the past year.
Price Volatility
| ODTC volatility | |
|---|---|
| ODTC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ODTC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ODTC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Kevin Tang | www.odonate.com |
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023.
Odonate, Inc. Fundamentals Summary
| ODTC fundamental statistics | |
|---|---|
| Market cap | US$53.25m |
| Earnings (TTM) | -US$102.07m |
| Revenue (TTM) | n/a |
Is ODTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ODTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.07m |
| Earnings | -US$102.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ODTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 10:21 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Odonate, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dana Flanders | Goldman Sachs |
| Michael Yee | Jefferies LLC |
| Eric Schmidt | TD Cowen |